BOT 2.27% 22.5¢ botanix pharmaceuticals ltd

Medical dermatology company Botanix Pharmaceuticals Limited...

  1. 26 Posts.
    Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT) is pleased to announce the receipt of Human Research Ethics Committee (HREC) approval and commencement of a patient study for its lead acne treatment product, BTX 1503. The announcement is available here for viewing.

    Key announcement highlights:
    • Botanix receives Human Research Ethics Committee approval to commence BTX 1503 acne patient study
    • Follows a successful Phase 1a study which showed excellent safety and tolerability of BTX 1503
    • Rapid recruitment expected to facilitate study completion by the end of December 2017
    • Positions BTX 1503 well for advancement into a Phase 2 safety and efficacy study under a FDA process in the USA in early 2018
    For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
0.005(2.27%)
Mkt cap ! $354.4M
Open High Low Value Volume
22.5¢ 24.0¢ 22.0¢ $2.251M 9.851M

Buyers (Bids)

No. Vol. Price($)
5 350473 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 140208 4
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
22.5¢
  Change
0.005 ( 2.27 %)
Open High Low Volume
22.5¢ 24.0¢ 22.0¢ 4728143
Last updated 15.58pm 29/03/2024 ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.